AP2014007499A0 - Antibodies to PCSK9 and uses thereof - Google Patents

Antibodies to PCSK9 and uses thereof

Info

Publication number: AP2014007499A0
Authority: AP; ARIPO
Prior art keywords: pcsk9; antibodies
Prior art date: 2011-09-16

Application number

AP2014007499A

Other languages

English (en)

Inventor

Julian Davies

Barrett Allan

Ryan James Darling

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-16

Filing date

2012-09-12

Publication date

2014-03-31

2012-09-12 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2014-03-31 Publication of AP2014007499A0 publication Critical patent/AP2014007499A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Obesity (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AP2014007499A 2011-09-16 2012-09-12 Antibodies to PCSK9 and uses thereof AP2014007499A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161535625P	2011-09-16	2011-09-16
PCT/US2012/054737 WO2013039958A1 (en)	2011-09-16	2012-09-12	Antibodies to pcsk9 and uses thereof

Publications (1)

Publication Number	Publication Date
AP2014007499A0 true AP2014007499A0 (en)	2014-03-31

Family

ID=46881177

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2014007499A AP2014007499A0 (en)	2011-09-16	2012-09-12	Antibodies to PCSK9 and uses thereof

Country Status (29)

Country	Link
US (1)	US8530414B2 (es)
EP (1)	EP2756003A1 (es)
JP (1)	JP6013487B2 (es)
KR (1)	KR101607783B1 (es)
CN (1)	CN103781802B (es)
AP (1)	AP2014007499A0 (es)
AR (1)	AR087715A1 (es)
AU (1)	AU2012308786B2 (es)
BR (1)	BR112014005799A2 (es)
CA (1)	CA2845706C (es)
CL (1)	CL2014000590A1 (es)
CO (1)	CO6910164A2 (es)
CR (1)	CR20140087A (es)
DO (1)	DOP2014000041A (es)
EA (1)	EA024430B1 (es)
EC (1)	ECSP14013242A (es)
GT (1)	GT201400049A (es)
IL (1)	IL231282A0 (es)
MA (1)	MA35433B1 (es)
MX (1)	MX347475B (es)
MY (1)	MY168961A (es)
PE (1)	PE20141147A1 (es)
PH (1)	PH12014500576A1 (es)
SG (1)	SG2014014187A (es)
TN (1)	TN2014000094A1 (es)
TW (1)	TWI586687B (es)
UA (1)	UA114604C2 (es)
WO (1)	WO2013039958A1 (es)
ZA (1)	ZA201401267B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JOP20080381B1 (ar)	2007-08-23	2023-03-28	Amgen Inc	بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130064834A1 (en)	2008-12-15	2013-03-14	Regeneron Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar)	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MX347602B (es)	2011-01-28	2017-05-03	Sanofi Biotechnology	Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
AR087305A1 (es)	2011-07-28	2014-03-12	Regeneron Pharma	Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
PL4252857T3 (pl)	2011-09-16	2025-03-03	Regeneron Pharmaceuticals, Inc.	Sposoby redukowania poziomów lipoproteiny(a) poprzez podawanie inhibitora proproteinowej konwertazy subtylizyny keksyny-9 (pcsk9)
US9255154B2 (en)	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) *	2012-10-22	2018-08-28	Concievalve, Llc	Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en)	2013-05-30	2018-10-30	Regeneron Pharmaceuticals, Inc.	Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EP2810955A1 (en)	2013-06-07	2014-12-10	Sanofi	Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
CA2914721A1 (en)	2013-06-07	2014-12-11	Regeneron Pharmaceuticals, Inc.	Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
EP2862877A1 (en)	2013-10-18	2015-04-22	Sanofi	Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
WO2014209384A1 (en) *	2013-06-28	2014-12-31	Amgen Inc.	Methods for treating homozygous familial hypercholesterolema
JP6616298B2 (ja)	2013-11-12	2019-12-04	サノフィ・バイオテクノロジー	Ｐｃｓｋ９阻害剤と共に使用するための投薬レジメン
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US9045548B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en)	2014-07-15	2015-04-28	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
US8883157B1 (en)	2013-12-17	2014-11-11	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
US8945560B1 (en)	2014-07-15	2015-02-03	Kymab Limited	Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de)	2013-12-17	2015-10-20	Kymab Limited	Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9034332B1 (en)	2014-07-15	2015-05-19	Kymab Limited	Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en)	2014-07-15	2015-06-09	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9023359B1 (en)	2014-07-15	2015-05-05	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
CN105085684B (zh) *	2014-05-14	2020-04-17	上海亨臻实业有限公司	Pcsk9靶向重组疫苗设计及其应用
DE202015009006U1 (de)	2014-07-15	2016-08-19	Kymab Limited	Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP2975059A1 (en)	2014-07-15	2016-01-20	Kymab Limited	Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9150660B1 (en)	2014-07-15	2015-10-06	Kymab Limited	Precision Medicine by targeting human NAV1.8 variants for treatment of pain
EP4328245A3 (en)	2014-07-15	2024-06-05	Kymab Ltd.	Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
CA2955294A1 (en)	2014-07-16	2016-01-21	Sanofi Biotechnology	Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
WO2016023916A1 (en)	2014-08-12	2016-02-18	Kymab Limited	Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en)	2014-11-07	2016-05-12	Kymab Limited	Treatment of disease using ligand binding to targets of interest
AU2016235662B2 (en) *	2015-03-20	2020-07-30	Aarhus Universitet	Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders
US10772956B2 (en)	2015-08-18	2020-09-15	Regeneron Pharmaceuticals, Inc.	Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
US11052175B2 (en)	2015-08-19	2021-07-06	Musculoskeletal Transplant Foundation	Cartilage-derived implants and methods of making and using same
CN106810609A (zh) *	2015-11-27	2017-06-09	苏州君盟生物医药科技有限公司	抗pcsk9抗体及其应用
US10793643B2 (en)	2015-12-31	2020-10-06	Jiangsu Hengrui Medicine Co., Ltd.	PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof
US20200270365A1 (en) *	2016-01-05	2020-08-27	Jiangsu Hengrui Medicine Co., Ltd.	Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
JP7461741B2 (ja)	2016-06-20	2024-04-04	カイマブ・リミテッド	抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018054240A1 (en) *	2016-09-20	2018-03-29	Wuxi Biologics (Shanghai) Co. Ltd.	Novel anti-pcsk9 antibodies
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JOP20190112A1 (ar)	2016-11-14	2019-05-14	Amgen Inc	علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
CN108424457B (zh) *	2017-02-13	2021-06-01	成都金洛克锶生物技术有限公司	针对pcsk9抗体与检测试剂盒的制备及其用途
CA3058567A1 (en)	2017-04-13	2018-10-18	Cadila Healthcare Limited	Novel peptide based pcsk9 vaccine
CR20210441A (es)	2019-01-18	2022-03-11	Astrazeneca Ab	Inhibidores de la pcsk9 y métodos de uso de los mismos
WO2020236670A1 (en)	2019-05-17	2020-11-26	Regeneron Pharmaceuticals, Inc.	Genome-based methods for reducing cardiovascular risk
CN114369164A (zh) *	2020-10-15	2022-04-19	苏州君盟生物医药科技有限公司	抗pcsk9单克隆抗体的生产工艺

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001031007A2 (en)	1999-10-22	2001-05-03	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules derived from rat brain and programmed cell death models
AU2001280471A1 (en)	2000-08-11	2002-02-25	Eli Lilly And Company	Novel secreted proteins and their uses
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
WO2008133647A2 (en)	2006-11-07	2008-11-06	Merck & Co., Inc.	Antagonists of pcsk9
US20100041102A1 (en)	2006-11-07	2010-02-18	Ayesha Sitlani	Antagonists of pcsk9
US20100040611A1 (en)	2006-11-07	2010-02-18	Sparrow Carl P	Antagonists of pcsk9
US20100150937A1 (en)	2006-11-07	2010-06-17	Sparrow Carl P	Antagonists of pcsk9
WO2008125623A2 (en)	2007-04-13	2008-10-23	Novartis Ag	Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
JOP20080381B1 (ar)	2007-08-23	2023-03-28	Amgen Inc	بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
SG2013014352A (en) *	2007-10-26	2014-09-26	Merck Sharp & Dohme	Anti-pcsk9 and methods for treating lipid and cholesterol disorders
AR070316A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) *	2008-02-07	2010-03-31	Merck & Co Inc	Anticuerpos 1b20 antagonistas de pcsk9
EP2296694B1 (en)	2008-04-23	2015-08-05	Amgen Inc.	Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
TWI445716B (zh) *	2008-09-12	2014-07-21	Rinat Neuroscience Corp	Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) *	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2011053759A1 (en)	2009-10-30	2011-05-05	Merck Sharp & Dohme Corp.	Ax1 and ax189 pcsk9 antagonists and variants
AR079336A1 (es)	2009-12-11	2012-01-18	Irm Llc	Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
BR112012022917A2 (pt) *	2010-03-11	2017-01-10	Pfizer	anticorpos com ligação a antígeno dependente de ph

2012
- 2012-08-29 AR ARP120103190A patent/AR087715A1/es unknown
- 2012-08-31 TW TW101131954A patent/TWI586687B/zh not_active IP Right Cessation
- 2012-09-12 EP EP12761863.5A patent/EP2756003A1/en not_active Withdrawn
- 2012-09-12 BR BR112014005799A patent/BR112014005799A2/pt active Search and Examination
- 2012-09-12 EA EA201490470A patent/EA024430B1/ru not_active IP Right Cessation
- 2012-09-12 CA CA2845706A patent/CA2845706C/en not_active Expired - Fee Related
- 2012-09-12 PH PH1/2014/500576A patent/PH12014500576A1/en unknown
- 2012-09-12 MX MX2014003175A patent/MX347475B/es active IP Right Grant
- 2012-09-12 UA UAA201401793A patent/UA114604C2/uk unknown
- 2012-09-12 KR KR1020147006577A patent/KR101607783B1/ko not_active Expired - Fee Related
- 2012-09-12 MY MYPI2014700618A patent/MY168961A/en unknown
- 2012-09-12 CN CN201280044580.3A patent/CN103781802B/zh not_active Expired - Fee Related
- 2012-09-12 SG SG2014014187A patent/SG2014014187A/en unknown
- 2012-09-12 WO PCT/US2012/054737 patent/WO2013039958A1/en not_active Ceased
- 2012-09-12 PE PE2014000352A patent/PE20141147A1/es not_active Application Discontinuation
- 2012-09-12 US US13/611,196 patent/US8530414B2/en not_active Expired - Fee Related
- 2012-09-12 AU AU2012308786A patent/AU2012308786B2/en not_active Ceased
- 2012-09-12 JP JP2014530744A patent/JP6013487B2/ja not_active Expired - Fee Related
- 2012-09-12 AP AP2014007499A patent/AP2014007499A0/xx unknown
2014
- 2014-02-19 ZA ZA2014/01267A patent/ZA201401267B/en unknown
- 2014-02-24 CR CR20140087A patent/CR20140087A/es unknown
- 2014-02-26 DO DO2014000041A patent/DOP2014000041A/es unknown
- 2014-03-03 IL IL231282A patent/IL231282A0/en unknown
- 2014-03-06 TN TNP2014000094A patent/TN2014000094A1/en unknown
- 2014-03-11 MA MA36818A patent/MA35433B1/fr unknown
- 2014-03-12 CL CL2014000590A patent/CL2014000590A1/es unknown
- 2014-03-13 GT GT201400049A patent/GT201400049A/es unknown
- 2014-03-13 EC ECSP14013242 patent/ECSP14013242A/es unknown
- 2014-03-14 CO CO14055604A patent/CO6910164A2/es active IP Right Grant

Also Published As

Publication number	Publication date
UA114604C2 (uk)	2017-07-10
US8530414B2 (en)	2013-09-10
JP2014530188A (ja)	2014-11-17
PH12014500576A1 (en)	2014-04-28
TWI586687B (zh)	2017-06-11
ECSP14013242A (es)	2014-07-31
WO2013039958A1 (en)	2013-03-21
CR20140087A (es)	2014-05-02
SG2014014187A (en)	2014-05-29
CO6910164A2 (es)	2014-03-31
EP2756003A1 (en)	2014-07-23
CA2845706C (en)	2016-03-22
CN103781802A (zh)	2014-05-07
AR087715A1 (es)	2014-04-09
PE20141147A1 (es)	2014-09-22
EA201490470A1 (ru)	2014-06-30
KR20140044939A (ko)	2014-04-15
BR112014005799A2 (pt)	2017-03-28
MX347475B (es)	2017-04-27
DOP2014000041A (es)	2014-06-30
AU2012308786B2 (en)	2016-12-15
TN2014000094A1 (en)	2015-07-01
TW201323444A (zh)	2013-06-16
IL231282A0 (en)	2014-04-30
KR101607783B1 (ko)	2016-03-30
EA024430B1 (ru)	2016-09-30
NZ622393A (en)	2015-11-27
MX2014003175A (es)	2015-03-05
CL2014000590A1 (es)	2014-10-17
MA35433B1 (fr)	2014-09-01
CN103781802B (zh)	2016-08-24
US20130071405A1 (en)	2013-03-21
MY168961A (en)	2019-01-28
JP6013487B2 (ja)	2016-10-25
CA2845706A1 (en)	2013-03-21
GT201400049A (es)	2015-05-28
AU2012308786A1 (en)	2014-02-27
ZA201401267B (en)	2015-11-25

Publication	Publication Date	Title
IL288203B (en)	2022-10-01	Meditops and Meditop binding antibodies and their use
IL281250A (en)	2021-04-29	Anti-PHF-tau antibodies and uses thereof
IL231282A0 (en)	2014-04-30	Antibodies to 9pcsk and their uses
IL259436A (en)	2018-07-31	Antibodies against 3angptl and their uses
DK2729170T3 (en)	2022-03-21	Antibody variants and uses thereof
IL232399A0 (en)	2014-06-30	Anti-2fgfr antibodies and their use
EP2756094A4 (en)	2015-05-06	ANTI-B7-H4 ANTIBODIES AND USES THEREOF
IL232055B (en)	2020-11-30	Anti-1htra antibodies and methods of use
IL238366A0 (en)	2015-06-30	Antibodies to interleukin-6 and their uses
HK1196139A (en)	2014-12-05	Antibodies to pcsk9 and uses thereof